- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07893964
TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS (TRICERATOPS)
A Randomized Placebo-Controlled TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS- The TRICERATOPS Study
A Randomized Placebo-Controlled TRIal of PPF3 vs. PlaCEbo in the TReatment of children and AdolescenTs with NeurOdeveloPmental DisorderS
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ches Souru, MD
- Phone Number: 3297 416-425-6220
- Email: csouru@hollandbloorview.ca
Study Contact Backup
- Name: Evdokia Anagnostou, MD
- Phone Number: 416-753-6005
- Email: eanagnostou@hollandbloorview.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 0A4
- Not yet recruiting
- McMaster University
-
Contact:
- Shamama Raza
- Phone Number: 3297 razas19@mcmaster.ca
- Email: razas19@mcmaster.ca
-
Principal Investigator:
- Elisabetta Trinari, MD
-
Kingston, Ontario, Canada, K7L 3N6
- Not yet recruiting
- Queen's University
-
Contact:
- Stamatoula Pasvanis
- Phone Number: 76923 613-533-6000
- Email: s.pasvanis@queensu.ca
-
Principal Investigator:
- Marc Woodbury-Smith, MD
-
London, Ontario, Canada, N6A 5W9
- Not yet recruiting
- London Health Sciences Centre
-
Principal Investigator:
- Janys Lim, MD
-
Contact:
- Kayleigh Tam
- Phone Number: 75556 519.685.8500
- Email: Kayleigh.Tam@lhsc.on.ca
-
Toronto, Ontario, Canada, M4G 1R8
- Recruiting
- Holland Bloorview Kids Rehabilitation Hospital
-
Principal Investigator:
- Evdokia Anagnostou, MD
-
Contact:
- Ches Souru, MD
- Phone Number: 3297 416-425-6220
- Email: csouru@hollandbloorview.ca
-
Contact:
- Evdokia Anagnostou, MD
- Phone Number: 416-753-6005
- Email: eanagnostou@hollandbloorview.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Outpatients 8-17 years of age, inclusive, with a weight ≥ 30 kg.
-
Already have participated in POND cohort
-
Females of childbearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.
-
Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria (American Psychiatric Association, 2013) for ASD. Diagnosis will be supported by the ADOS-2. Diagnostic and Statistical Manual (DSM-5) criteria will be established by a clinician with expertise with individuals with ASD.
-
Have a Clinical Global Impression-Severity (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill)
-
If already receiving interventions, must meet the following criteria:
-
If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening (6 weeks for Fluoxetine) and will not electively modify ongoing medications for the study duration.
b. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions.
-
Have a negative pregnancy test at screening for patients who have experienced menarche
-
Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Qualified Investigator.
Ability to obtain written informed consent from the participant, if developmentally appropriate. If a participant does not have the capacity to consent, ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)/legal guardian.
Exclusion Criteria:
Please contact the site for details
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm 1
PPF3 |
Investigational |
|
Placebo Comparator: Arm 2
Placebo |
Placebo |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse event
Time Frame: From enrollment to the end of week 16
|
From enrollment to the end of week 16
|
|
Clinical Global Impression Scale
Time Frame: From Screening to Week 16
|
From Screening to Week 16
|
Collaborators and Investigators
Investigators
- Principal Investigator: Evdokia Anagnostou, MD, Holland Bloorview Kids Rehabilitation Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PPF3-10-2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.